Onconova Therapeutics Inc (ONTX) stock has gained 14.81% over the past week and gets a Bearish rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With ONTX Stock Today?
Onconova Therapeutics Inc (ONTX) stock has gained 13.21% while the S&P 500 has fallen -0.32% as of 11:02 AM on Tuesday, Oct 13. ONTX has risen $0.04 from the previous closing price of $0.27 on volume of 13,200,193 shares. Over the past year the S&P 500 has gained 18.77% while ONTX has fallen -63.10%. ONTX lost -$0.97 per share in the over the last 12 months.
To screen for more stocks like Onconova Therapeutics Inc click here.
More About Onconova Therapeutics Inc
Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks signaling by targeting RAS effeccellular tor pathways.
Click Here to get the full Stock Score Report on Onconova Therapeutics Inc (ONTX) Stock.
